Shares of MiMedx Group Inc. (NASDAQ:MDXG) were up 2.8% during trading on Monday . The company traded as high as $7.86 and last traded at $7.70, with a volume of 660,177 shares traded. The stock had previously closed at $7.49.

A number of analysts recently commented on MDXG shares. Needham & Company LLC reiterated a “strong-buy” rating and issued a $12.00 target price (down from $13.00) on shares of MiMedx Group in a research note on Thursday, April 7th. Lake Street Capital reduced their price target on shares of MiMedx Group from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, April 19th. Zacks Investment Research lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. First Analysis lowered shares of MiMedx Group from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $14.00 to $9.00 in a research report on Wednesday, April 27th. Finally, Brean Capital reissued a “buy” rating on shares of MiMedx Group in a research report on Thursday, May 12th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. MiMedx Group has a consensus rating of “Buy” and a consensus target price of $10.89.

The firm’s 50-day moving average is $7.78 and its 200-day moving average is $7.97. The stock has a market capitalization of $848.27 million and a PE ratio of 36.54.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Tuesday, July 26th. The company reported $0.05 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.02. The company had revenue of $57 million for the quarter, compared to analysts’ expectations of $56.49 million. The business’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 EPS. On average, equities research analysts anticipate that MiMedx Group Inc. will post $0.26 earnings per share for the current year.

In related news, insider William Charles Taylor sold 29,112 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $7.55, for a total value of $219,795.60. Following the completion of the transaction, the insider now directly owns 612,316 shares of the company’s stock, valued at $4,622,985.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Parker H. Petit purchased 50,000 shares of the stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average cost of $6.74 per share, with a total value of $337,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,919,121 shares of the company’s stock, valued at $33,154,875.54. The disclosure for this purchase can be found here.

A number of institutional investors have made changes to their positions in MDXG. Wells Fargo & Company MN increased its position in shares of MiMedx Group by 19.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,041,546 shares of the company’s stock worth $9,759,000 after buying an additional 169,102 shares during the period. Parsons Capital Management Inc. RI increased its position in shares of MiMedx Group by 1.5% in the fourth quarter. Parsons Capital Management Inc. RI now owns 718,700 shares of the company’s stock worth $6,734,000 after buying an additional 10,650 shares during the period. Principal Financial Group Inc. increased its position in shares of MiMedx Group by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 672,248 shares of the company’s stock worth $6,299,000 after buying an additional 29,523 shares during the period. Russell Frank Co increased its position in shares of MiMedx Group by 3.2% in the fourth quarter. Russell Frank Co now owns 403,005 shares of the company’s stock worth $3,840,000 after buying an additional 12,499 shares during the period. Finally, California State Teachers Retirement System increased its position in shares of MiMedx Group by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 201,312 shares of the company’s stock worth $1,886,000 after buying an additional 3,213 shares during the period.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.